Monitoring high-risk individuals for liver cancer using liquid biopsy
A Prospective Study on the Application of Liquid Biopsy in the Surveillance of High-risk Population of Hepatocellular Carcionoma.
This study is testing a new blood test to see if it can help find liver cancer early in people who are at high risk due to chronic liver diseases.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 1000 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Tianjin Third Central Hospital Academic / other |
| Locations | 1 site (Tianjin, Tianjin) |
| Trial ID | NCT06134973 on ClinicalTrials.gov |
What this trial studies
This study focuses on the application of liquid biopsy technology to monitor high-risk populations for Hepatocellular Carcinoma (HCC). By utilizing high-throughput sequencing to analyze plasma free DNA, the study aims to detect early signs of cancer in patients with chronic liver diseases. The collaboration with BGI enhances the technical capabilities for next-generation sequencing, providing a novel approach to cancer surveillance. The goal is to improve early detection rates of liver cancer, which is crucial for effective treatment and better patient outcomes.
Who should consider this trial
Good fit: Ideal candidates include individuals diagnosed with chronic liver diseases such as chronic hepatitis B, chronic hepatitis C, or fatty liver, who have detectable intrahepatic nodules.
Not a fit: Patients with previously diagnosed malignant tumors or those unable to cooperate with blood sampling may not benefit from this study.
Why it matters
Potential benefit: If successful, this approach could significantly enhance early detection of liver cancer, leading to improved survival rates for patients.
How similar studies have performed: Other studies have shown promise in using liquid biopsy for cancer detection, indicating that this approach is gaining traction in the field.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Patients diagnosed as chronic liver disease, including but not limited to chronic hepatitis B, chronic hepatitis C, fatty liver; 2. Intrahepatic nodules detectable by ultrasound; 3. Unlimited number of nodules; 4. The patient has signed an informed consent form. Exclusion Criteria: 1. Previously diagnosed malignant tumors； 2. Patients who are unable to cooperate with venous blood sampling； 3. According to the judgment of the investigator, the participants are not suitable to participate in this study.
Where this trial is running
Tianjin, Tianjin
- 王芳 — Tianjin, Tianjin, China (Recruiting)
Study contacts
- Principal investigator: Fengmei Wang, PhD — Tianjin Third Central Hospital
- Study coordinator: Fengmei Wang, PhD
- Email: wangfengmeitj@126.com
- Phone: 15522242696
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.